BRAF and non-small cell lung carcinoma: NSCLC is further divided into adeno‐ (AD), squamous cell (SQ) and other histological subtypes such as large‐cell carcinoma,4 and AD patients may harbour common oncogenic driver alterations, that is, Kirsten rat sarcoma virus (KRAS, about 30%), epidermal growth factor receptor (EGFR) (14%–30%), BRAF (5%–7%), anaplastic lymphoma receptor (ALK) (1%–5%), MET Proto‐Oncogene, Receptor Tyrosine Kinase (METs) (1%–3%) and ERBB2 (2%–6%).5, 6